The US Food and Drug
Administration has granted
accelerated approval to Praxbind
(idarucizumab) for patients taking
the novel anticoagulant Pradaxa
(dabigatran) during emergency
situations where there is a need to
reverse Pradaxa’s blood-thinning
effects.
Praxbind is the first reversal agent
approved specifically for Pradaxa,
and works by binding the drug
compound to neutralise its effect.
The Praxbind labelling
recommends patients resume their
anticoagulant therapy as soon as
medically appropriate.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Oct 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.